15. LIFE ON LAND

Lantheus (NASDAQ:LNTH) Stock Rating Reaffirmed by Truist Financial

Written by Amanda

Lantheus (NASDAQ:LNTHGet Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at Truist Financial in a research note issued on Monday, Benzinga reports. They presently have a $82.00 price objective on the medical equipment provider’s stock, up from their prior price objective of $80.00. Truist Financial’s target price would indicate a potential upside of 23.68% from the company’s previous close.

Several other analysts have also commented on the company. TD Cowen assumed coverage on Lantheus in a report on Monday, December 4th. They set an “outperform” rating and a $100.00 target price on the stock. William Blair lowered Lantheus from an “outperform” rating to a “market perform” rating in a report on Monday, December 18th. TheStreet lowered Lantheus from a “b-” rating to a “c” rating in a report on Monday, December 18th. B. Riley dropped their price objective on Lantheus from $113.00 to $95.00 and set a “buy” rating on the stock in a report on Wednesday, January 10th. Finally, Brookline Capital Management started coverage on Lantheus in a report on Thursday, November 30th. They issued a “buy” rating and a $100.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Lantheus has a consensus rating of “Moderate Buy” and an average price target of $104.14.

Check Out Our Latest Stock Report on Lantheus

Lantheus Stock Up 0.0 %

Lantheus stock opened at $66.30 on Monday. The firm has a market cap of $4.54 billion, a price-to-earnings ratio of 14.29 and a beta of 0.53. Lantheus has a 52 week low of $50.20 and a 52 week high of $100.85. The business’s 50-day moving average price is $57.65 and its 200 day moving average price is $64.29. The company has a quick ratio of 5.45, a current ratio of 5.80 and a debt-to-equity ratio of 0.69.

Hedge Funds Weigh In On Lantheus

Institutional investors have recently added to or reduced their stakes in the stock. Covestor Ltd raised its position in Lantheus by 102.5% in the second quarter. Covestor Ltd now owns 324 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 164 shares during the period. Tucker Asset Management LLC raised its position in Lantheus by 239.0% in the third quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 282 shares during the period. Parkside Financial Bank & Trust raised its position in Lantheus by 60.2% in the second quarter. Parkside Financial Bank & Trust now owns 426 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 160 shares during the period. First Horizon Advisors Inc. raised its position in Lantheus by 97.0% in the third quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 225 shares during the period. Finally, Principal Securities Inc. purchased a new stake in Lantheus in the fourth quarter valued at $28,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

(Get Free Report)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent.

Featured Articles

Analyst Recommendations for Lantheus (NASDAQ:LNTH)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Lantheus, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Lantheus wasn’t on the list.

While Lantheus currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Click the link below and we’ll send you MarketBeat’s list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Source: marketbeat.com

Lantheus (NASDAQ:LNTHGet Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at Truist Financial in a research note issued on Monday, Benzinga reports. They presently have a $82.00 price objective on the medical equipment provider’s stock, up from their prior price objective of $80.00. Truist Financial’s target price would indicate a potential upside of 23.68% from the company’s previous close.

Several other analysts have also commented on the company. TD Cowen assumed coverage on Lantheus in a report on Monday, December 4th. They set an “outperform” rating and a $100.00 target price on the stock. William Blair lowered Lantheus from an “outperform” rating to a “market perform” rating in a report on Monday, December 18th. TheStreet lowered Lantheus from a “b-” rating to a “c” rating in a report on Monday, December 18th. B. Riley dropped their price objective on Lantheus from $113.00 to $95.00 and set a “buy” rating on the stock in a report on Wednesday, January 10th. Finally, Brookline Capital Management started coverage on Lantheus in a report on Thursday, November 30th. They issued a “buy” rating and a $100.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Lantheus has a consensus rating of “Moderate Buy” and an average price target of $104.14.

Check Out Our Latest Stock Report on Lantheus

Lantheus Stock Up 0.0 %

Lantheus stock opened at $66.30 on Monday. The firm has a market cap of $4.54 billion, a price-to-earnings ratio of 14.29 and a beta of 0.53. Lantheus has a 52 week low of $50.20 and a 52 week high of $100.85. The business’s 50-day moving average price is $57.65 and its 200 day moving average price is $64.29. The company has a quick ratio of 5.45, a current ratio of 5.80 and a debt-to-equity ratio of 0.69.

Hedge Funds Weigh In On Lantheus

Institutional investors have recently added to or reduced their stakes in the stock. Covestor Ltd raised its position in Lantheus by 102.5% in the second quarter. Covestor Ltd now owns 324 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 164 shares during the period. Tucker Asset Management LLC raised its position in Lantheus by 239.0% in the third quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 282 shares during the period. Parkside Financial Bank & Trust raised its position in Lantheus by 60.2% in the second quarter. Parkside Financial Bank & Trust now owns 426 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 160 shares during the period. First Horizon Advisors Inc. raised its position in Lantheus by 97.0% in the third quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 225 shares during the period. Finally, Principal Securities Inc. purchased a new stake in Lantheus in the fourth quarter valued at $28,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

(Get Free Report)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent.

Featured Articles

Analyst Recommendations for Lantheus (NASDAQ:LNTH)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Lantheus, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Lantheus wasn’t on the list.

While Lantheus currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Click the link below and we’ll send you MarketBeat’s list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Source: marketbeat.com

About the author

Amanda

Hi there, I am Amanda and I work as an editor at impactinvesting.ai;  if you are interested in my services, please reach me at amanda.impactinvesting.ai

Leave a Comment